The treatment of wet AMD in the United States has been mainly dominated by three anti-VEGF therapies: Roche / Genentech’s off-label Avastin, Roche / Genentech’s Lucentis, and Regeneron’s Eylea. The market is becoming increasingly fragmented; newer entrants Roche’s Vabysmo and Regeneron’s Eylea HD are being increasingly incorporated into the treatment algorithm of wet AMD patients, while competition from biosimilars grows. Using national, longitudinal, patient-level U.S. claims data, this report examines recent trends in the management of wet AMD both among newly diagnosed patients and among patients filling a prescription for a key therapy.
Questions answered
Markets covered: United States
Key companies: Roche / Genentech, Regeneron, Novartis, Biogen, Samsung Bioepis
Key drugs: Avastin, Eylea, Lucentis, Beovu, Mvasi, Zirabev, Vabysmo, Susvimo, Byooviz, Cimerli
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses